ArticleCancer medicine2025
Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThrombocytopenia is less common but shows high risk of early mortality in newly diagnosed multiple myeloma (NDMM) patients. In the era of novel agents-based induction therapy (NAIT), it is unclear whether NAIT can overcome the poor prognosis associated with thrombocytopenia.
objectivesTo evaluate the prognostic implications of thrombocytopenia in NDMM patients.
methodsWe retrospectively analyzed 1363 NDMM patients baseline characteristics, treatment response and survival, further performed regression analysis, constructed a nomogram model to predict progression free survival (PFS), and further internally validated this model.
resultsOverall, 211 (15.48%) NDMM patients were harboring thrombocytopenia, with advanced disease stages and worse outcomes. Their PFS (15 months vs 21.5 months, p < 0.001)and overall survival (47 months vs 77 months, p < 0.001) were significantly inferior compared with patients without thrombocytopenia. In NDMM receiving NAIT, the overall response (87.8% vs 92.4%, p = 0.33) but not deep response or survival could be improved between patients with and without thrombocytopenia. Five important variables (thrombocytopenia, R-ISS stage III, NAIT, deep response and autologous stem-cell transplantation) in multivariate Cox analysis were incorporated in the nomogram, which was further validated by internal datasets. The Calibration curve and time-dependent Receiver operating characteristic showed that the model accurately predicted the 12- and 24- months PFS of NDMM patients.
conclusionsThrombocytopenia has an indispensable prognostic effect in decreasing responses to induction therapy and survival in NDMM patients. Thrombocytopenia might need to be regarded as an independent prognostic factor in risk stratification of Chinese NDMM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.